Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Intellia Therapeutics, Inc. (NTLA)

33.1   -0.89 (-2.62%) 09-21 12:30
Open: 33.34 Pre. Close: 33.99
High: 33.41 Low: 32.64
Volume: 342,072 Market Cap: 2,929(M)

Technical analysis

as of: 2023-09-21 12:18:25 PM
Short-term rate:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Mid-term rate:       
Target: Six months: 42.72     One year: 45.56
Support: Support1: 32.63    Support2: 27.15
Resistance: Resistance1: 36.57    Resistance2: 39
Pivot: 36.4
Moving Average: MA(5): 34.45     MA(20): 36.8
MA(100): 40.67     MA(250): 42.1
MACD: MACD(12,26): -1.4     Signal(9): -1.1
Stochastic oscillator: %K(14,3): 7.3     %D(3): 7
RSI: RSI(14): 24.2
52-week: High: 63.11  Low: 32.43
Average Vol(K): 3-Month: 749 (K)  10-Days: 771 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ NTLA ] has closed below the lower bollinger band by 0.4%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 7.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 34.99 - 35.24 35.24 - 35.42
Low: 33.24 - 33.57 33.57 - 33.82
Close: 33.54 - 33.98 33.98 - 34.32

Company Description

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has license and collaboration agreements with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease; Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; Ospedale San Raffaele; and a strategic collaboration with SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. The company was formerly known as AZRN, Inc. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Headline News

Mon, 18 Sep 2023
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Rating of ... - MarketBeat

Wed, 13 Sep 2023
Intellia Therapeutics Enters Oversold Territory (NTLA) - Nasdaq

Wed, 13 Sep 2023
Workhorse Receives IRS Approval for Commercial Clean Vehicle ... - Best Stocks

Sat, 09 Sep 2023
10 Biotech Stocks with Biggest Upside - Yahoo Finance

Thu, 31 Aug 2023
The 3 Most Promising Biotech Stocks to Own Now - InvestorPlace

Tue, 29 Aug 2023
Discovery Value Fund Sells 11389 Shares of Intellia Therapeutics ... - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 88 (M)
Shares Float 84 (M)
% Held by Insiders 5.3 (%)
% Held by Institutions 87.9 (%)
Shares Short 7,290 (K)
Shares Short P.Month 6,210 (K)

Stock Financials

EPS -5.41
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.51
Profit Margin (%) 0
Operating Margin (%) -867.2
Return on Assets (ttm) -23.7
Return on Equity (ttm) -45.7
Qtrly Rev. Growth -3.1
Gross Profit (p.s.) -4.16
Sales Per Share 0.59
EBITDA (p.s.) -5.11
Qtrly Earnings Growth 0
Operating Cash Flow -368 (M)
Levered Free Cash Flow -224 (M)

Stock Valuations

PE Ratio -6.12
PEG Ratio -0.3
Price to Book value 2.64
Price to Sales 55.22
Price to Cash Flow -7.96

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.